Clinical trials: Glioblastoma
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma Multiforme of Brain, Glioma
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic…
- Conditions
- Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
- Trial name
- NCT07464925
- Testing
- GLIX1
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tetragon Biosciences Ltd
Recurrent Glioblastoma, IDH-Wildtype
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma.
- Trial name
- Cerebraca-02/3 (NCT07349693)
- Testing
- Cerebraca wafer, Temozolomide (for relapsed malignant glioma)
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Everfront Biotech Co., Ltd.
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Gastrointestinal Stromal Tumors, GIST
A Drug-drug Interaction Study of Avapritinib and Midazolam
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)…
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Trial name
- NCT04908176
- Testing
- Avapritinib, midazolam
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Blueprint Medicines Corporation
Malignant Glioma, Glioblastoma Multiforme
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL13-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00041587
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- INSYS Therapeutics Inc
Malignant Glioma, Glioblastoma Multiforme
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
The experimental anti-cancer drug IL13-PE38QQR, which is being developed for the treatment of malignant brain tumors, is composed of parts of two proteins: the immune system cytokine IL13 and a toxin from the bacterium…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00064779
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Glioblastoma Multiforme
Nativis Voyager for Newly Diagnosed GBM
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and…
- Trial name
- NAT109 (NCT03276286)
- Testing
- Nativis Voyager
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Nativis, Inc.
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Glioblastoma
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent…
- Trial name
- NCT01632228
- Testing
- Bevacizumab, Onartuzumab
- Where
- 62 sites in United States, Canada and 6 more
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma Multiforme
NG101m Adjuvant Therapy in Glioblastoma Patients
The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme.
- Trial name
- NCT04373785
- Testing
- Intensity-modulated radiation therapy, Temozolomide, NG101m
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- NeuGATE Theranostics
GBM
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
This is a multicenter, randomized, controlled study, aiming to evaluate the efficacy and safety of CAN008 administered once-weekly with rRT for treating first tumor recurrence in patients with GBM.
- Trial name
- NCT03746288
- Testing
- CAN008
- Volunteers
- 60 people
- Sponsor
- CANbridge Life Sciences Ltd.
Cancer
A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A).
- Trial name
- NCT01812603
- Testing
- Sativex
- Where
- 5 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- Jazz Pharmaceuticals